baseline ileocolonoscopy [11] . The definition of MH in CD as the total disappearance of ulcers is simple in clinical practice, but this binary statement does not take into account patients with evidence of MH under treatment with some remaining lesions, like erosions. For UC, the International Organization of IBD made a consensus in 2007 to define MH: the absence of friability, blood, erosions and ulcers in all visualized segments of the gut mucosa [12] . Presence of abnormal vascular pattern is compatible with MH according to panel experts [12] .
For the assessment of MH, clinicians require reproducible and validated scoring indices of disease activity ( table 1 ) [12] . There are three main endoscopic disease activity indices used in clinical trials for CD: the Crohn's Disease Endoscopic Index of Severity (CDEIS) [13] , the Simple Endoscopic Score for Crohn's Disease (SES-CD) [14] and the Rutgeerts score [15] . The CDEIS is a prospectively built scoring index, based on elementary CD lesions and the percentage of involvement of different ileocolonic segments [13] . The CDEIS, considered as the gold standard scoring index, is regarded as complex and this limits its usefulness in clinical practice, largely restricting it to the clinical trial setting. A simple index, the SES-CD has been developed and correlates well with the CDEIS [14] . SES-CD involves four variables: ulcer size, the extent of the ulcerated surface, the extent of the affected surface and stenosis in five bowel segments. However, the SES-CD is not validated. For both indices, there is no validated cut-off value for defining endoscopic remission, response or MH. Two cut-offs defining endoscopic remission (CDEIS ! 6) and complete MH (CDEIS ! 4) have been proposed [16] .
The Rutgeerts score is used in the postoperative setting to determine the presence and severity of endoscopic disease recurrence in the neoterminal ileum after ileal or ileocolonic resection [9] . Scoring is based on the presence of aphthous lesions, inflamed mucosa, nodules and narrowing, and ranges from i0 to i4 accordingly [9] . Most clinical trials have used i2 as a cut-off to define endoscopic recurrence. However, the Rutgeerts score still lacks validation.
In the small bowel, capsule endoscopy is increasingly used to assess the severity of CD [17] . Specific disease activity indices have been developed, but still await validation before using them in clinical trials and/or clinical practice [18] .
For UC, the first index was developed by Truelove and Witts [19] in a placebo-controlled trial on cortisone treatment. Thereafter, several endoscopic system scoring systems have been developed (e.g. the modified Baron score [20] and the Mayo endoscopic subscore [21] ) but none of them have been fully validated ( table 2 ) . Recently, Travis et al. [22] proposed a new endoscopic score, namely the Ulcerative Colitis Endoscopic Index of Severity. Development of this index was made in two phases in order to assess intra-and inter-individual variation in the overall endoscopic assessment of severity [22] . One of the major differences with the Mayo endoscopic subscore is the exclusion of the item 'friability' from the endoscopic description of severity [22] . This score is composed of the following items: vascular pattern, bleeding, erosions and ulcers; once it has been validated independently, it should be used mainly in clinical trials and clinical practice in the future [22] .
Induction and Maintenance of Mucosal Healing with Anti-TNF Agents

Induction
In the ACCENT 1 [23] trial, a randomized controlled trial evaluating the efficacy of infliximab for the treatment of refractory active CD, an endoscopic substudy [10] of 99 patients was performed. MH was observed at week 10 in 29% of patients (13/45) who had received induction therapy with three infusions of infliximab compared with 3% of patients (1/29, p = 0.006) who had received only one infusion at baseline [10] . Systematic maintenance therapy with infliximab therapy every 8 weeks allowed MH in 44% (16/36) of CD patients at week 54 compared to 18% (4/22, p = 0.041) in patients treated episodically [10] . In the SONIC trial, which compared infliximab monotherapy, azathioprine monotherapy and combined infliximab and azathioprine therapy for active luminal CD, MH was significantly higher in the combined arm (44%, p ! 0.001) at week 26 [24] .
The MUSIC trial is an open-label study that assessed the ability of certolizumab pegol to induce MH at 10 weeks in 89 CD patients with active disease [16] . Induction therapy consisted of subcutaneous injection at weeks 0, 2 and 4 followed by 1 injection at week 8. At 10 weeks, endoscopic remission (defined as CDEIS ! 6) was seen in 42%, but MH (defined as an absence of ulcers) was seen in only 5% of patients [16] . The EXTEND trial, evaluating the efficacy of adalimumab for the treatment of moderate to severe active ileocolonic CD, used MH at week 12 as a primary end point [9] . One hundred and thirtyfive CD patients received 160-mg and 80-mg induction therapy at weeks 0 and 2, respectively, and were then randomized at week 4 to blinded maintenance therapy with 40 mg ada limumab every other week or placebo up to week 52. The primary end point was achieved in 27% (17/62) of the adalimumab arm compared with 13% (8/61) of the placebo-treated patients (p = 0.056) [9] . At week 52, rates of MH were 24% and 0, respectively (p ! 0.001). Remission rates, based on CDEIS, were 52% for adalimumab and 28% for placebo at week 12 (p = 0.06) and 28 and 3%, respectively, at week 52 (p ! 0.01) [9] ( fig. 1 ).
In the ACT-1 and ACT-2 trials (Active Ulcerative Colitis Trials 1 and 2), [25, 26] infliximab or placebo were administered intravenously in 364 (in each study) patients with moderate to severe refractory UC. Induction therapy with infliximab 5 mg/kg given at weeks 0, 2 and 6 resulted at week 8 in MH in 62% of patients in the ACT-1 trial and in 60.3% of patients in ACT-2 compared with 33.9 and 30.9% in the placebo groups of each study (p ! 0.001 in both trials) [25, 26] . A small, openlabel study involving 20 patients evaluated the efficacy of adalimumab in patients with endoscopic evidence of active, moderate to severe, refractory UC [27] . Induction treatment with adalimumab 160 mg at week 0, 80 mg at week 2 and 40 mg every other week resulted in MH in 30% of patients at week 8 [27] . Finally, in the ULTRA 2 trial [28] , a randomized, double-blind, placebo-controlled trial, the efficacy of adalimumab in UC patients for induction was evaluated [28] . At week 8, MH was achieved in 41.1% of patients receiving adalimumab and 31.7% of patients receiving placebo (p = 0.032) [28] ( fig. 2 ) . [29] . D'Haens et al. [30] , demonstrated that early induction therapy with infliximab combined with azathioprine maintenance therapy resulted in a greater rate of MH at 14 weeks (73.1%) when compared to the step-up approach with steroids and azathioprine (30,4%, p = 0.0028) [30] . In the EXTEND trial, a significant difference was observed in terms of MH at 1 year in the maintenance therapy group with adalimumab compared to the placebo group (24 vs. 0%, respectively) [9] ( fig. 1 ).
In the postoperative setting, anti-TNF also allows maintenance of MH. In a randomized study, Regueiro et al. [31] studied 24 patients with CD who had undergone ileocolonic resection to receive intravenous infliximab, which was administered within 4 weeks of surgery and continued for 1 year, or placebo. The rate of recurrence (Rutgeerts score 6 i2) at 1 year was significantly lower in the infliximab group (9.1%) compared to the placebo group (84.6%, p = 0.0006) [31] .
For UC, in the ACT-1 trial, scheduled maintenance therapy with infliximab 5 mg/kg every 8 weeks resulted in MH in 45.5% of patients compared to 18.2% (p ! 0.001) in the placebo group at week 54 [25] . In the ULTRA 2 trial, MH in UC patients taking adalimumab every other week was achieved in 25 and 15.4% in the active arm and placebo group, respectively, (p = 0.032) at week 52 [28] ( fig. 2 ) .
Impact of Mucosal Healing on the Disease Course
Clinical Response/Remission
In the ACCENT 1 trial, patients who achieved MH with infliximab had a longer relapse-free disease course than those without MH [32] . Moreover, at week 54, a longer duration of clinical remission was observed in the complete MH group (20 weeks) compared to patients without complete MH (4 weeks) [32] . In a substudy of the ACCENT 1 trial, MH at weeks 10 and 54 was associated with higher clinical remission rates up to week 54, although these results were not statistically significant [29] .
A substudy of the 'step-up/top-down' trial focused on the value of the endoscopic assessment after 2 years of treatment on clinical outcomes at years 3 and 4. MH (defined as an SES-CD score of zero) at 2 years predicted stable sustained clinical remission in the following 2 years in 68 versus 35% of patients (p = 0.004) with endoscopic evidence of persistent disease activity (defined as an SES-CD score from 2 to 9) [33] . In a large retrospective cohort study involving 214 CD patients on anti-TNF therapy, Schnitzler et al. [11] evaluated the impact of MH on long-term outcomes. At 5 years, clinical remission was maintained in 65% (83/128) of patients with MH compared to 40% (34/86) of patients who did not achieve MH (p = 0.0004) [11] .
It has been demonstrated that the Rutgeerts score, which has become the gold standard for evaluating CD postoperative recurrence as the severity of endoscopic lesions at 1 year, is predictive of clinical recurrence [15] . A total of 89 CD patients who had been treated by ileal re- section were included in a prospective cohort study [15] . Three years after surgery, the endoscopic recurrence rate was 85% and symptomatic recurrence occurred in 34% [15] . Endoscopic disease often recurs after infliximab is stopped. In a prospective cohort study of 12 consecutive patients on a postoperative infliximab regimen, treatment was stopped 3 years after surgery. Discontinuation of infliximab resulted in endoscopic recurrence at 4 months in 10 of 12 patients (83%) [34] . For UC, similar findings were reported in a landmark study from 1966 [35] . Indeed, 40% of UC patients who achieved MH after acute treatment with oral and rectal corticosteroids remained asymptomatic during a 1-year follow-up [35] , whereas only 18% of patients who did not achieve MH after treatment remained asymptomatic during the same period [35] . In the ACT-1 and ACT-2 trials [25, 26] , the proportion of patients in clinical remission at week 30 of therapy was 4-fold greater for patients with MH at week 8 (48.3 vs. 9.5%, respectively).
Overall, these findings suggest that MH is associated with both a higher clinical response and lower relapse rates in both CD and UC [36] .
Hospitalizations
In the endoscopic substudy of the ACCENT I trial, patients achieving MH at both weeks 10 and 54 needed less CD-related hospitalizations (0%) compared to those with MH at only one of two visits (18.8%) or with no healing at either visit (28%) [29] . In a retrospective single-center cohort study evaluating the long-term outcome of infliximab in 214 patients with CD, patients who achieved MH needed hospitalization less frequently than patients who did not achieve it (42.2 vs. 59.3%, respectively, p = 0.0018) [11] .
For UC, Ardizzone et al. [37] showed that no MH after the first course of corticosteroid therapy was associated with a more aggressive disease course. Indeed, after multivariate analysis, lack of MH was the only factor associated with negative outcomes at 5 years, including hospitalization (HR 3.634, 95% CI 1.556-8.485, p = 0.0029) [37] .
Thus, MH is associated with lower hospitalization rates in both UC and CD [36] .
Surgery
Extensive and deep ulcerations in CD patients predicted a more aggressive clinical course with increased rates of penetrating complications and surgery [38] . In a retrospective single-center cohort study, Schnitzler et al. [11] found that patients who had MH on an infliximab regimen needed less abdominal surgeries than those who did not achieve MH [14.1 (12/89) vs. 38.4% (33/86), respectively; p ! 0.0001]. In a Norwegian populationbased cohort study involving 458 IBD patients, a greater proportion of CD patients [11% (6/53)] who achieved MH at 1 year were able to avoid surgical resection over a period of 5 years compared to 20% (18/88) who were without MH at 1 year (p = 0.10) [39] . Regarding UC, 2% of patients with MH at 1 year needed a surgical resection in 5 years compared to 7% of patients without MH (p = 0.02) [39] .
In a retrospective single-center study, Ferrante et al. [40] demonstrated that a longer colectomy-free survival was observed among UC patients who achieved MH (defined as a Mayo endoscopic subscore of 0 or 1) at week 4 or week 10.
Hence, MH is associated with a reduced need for surgery in both CD and UC [36] .
Colorectal Cancer
In a case-control study of 68 UC patients and 136 matched controls, the histological inflammation score was the only independent risk factor for the development of colorectal neoplasia (OR 4.69, 95% CI 2.10-10.48, p ! 0.001) [41] .
In a subsequent study, the same authors showed that macroscopically normal endoscopic findings returned the 5-year cancer risk to that of the general population (OR 0.38, 95% CI 0.19-0.73, p = 0.003) [42] . Rubin et al. [43] also demonstrated a higher risk of cancer and dysplasia in UC patients with a higher inflammatory activity score (OR 2.73, 95% CI 1.44-5.18, p = 0.002). Gupta et al. [44] confirmed that histological inflammation over time was associated with the progression towards advanced neoplasia in UC (HR 3, 95% CI 1.4-6.3).
MH is thus associated with a lower risk of colorectal cancer in UC; for CD, such data are lacking [36] .
Conclusion
The definition of MH is still under debate and no formal definition has been universally accepted. Except for CDEIS, all endoscopic indices still lack validation in both CD and UC. Anti-TNF therapy is the most potent drug class to induce and maintain MH in IBD. MH may change the natural course of the disease by decreasing the need for surgery and reducing hospitalization rates in both UC and CD. MH may also prevent the development of longterm disease complications, such as bowel damage in CD and colorectal cancer in UC. Schnitzler et al. [11] showed that MH predicts long-term outcome with maintenance therapy with infliximab in CD. The need for surgery was significantly different between the groups with and without MH (14 and 38.4%, respectively, p ! 0.0001). Interestingly, there was no difference between the groups with complete and partial MH (14 vs. 14.1%, respectively). Hence, further investigation is required in order to establish the degree of MH needed to change the course of disease.
